降脂新药临床试验折戟，科学家重新审视Lp(a)靶向疗法前景
曾被视为心血管领域突破的降脂蛋白(a)药物在一项关键试验中未显示获益，科研界正评估这一结果对后续研发的影响。
查看原文 ↗近期一项关键试验失败，同类III期读出多集中在2026-2027年且不确定性高，短期出现明确阳性结果概率偏低。
以药企官方公告或同行评议期刊/权威会议公布的III期主要终点结果为准，需明确达到主要心血管终点。
热点 · 结算 2027-02-03
Cassandra Willyard is a science journalist in Madison, Wisconsin.
Search author on: PubMed Google Scholar
Bluesky Facebook LinkedIn Reddit Whatsapp X Save article View saved research Lipoprotein(a) is a cholesterol-carrying molecule that raises the risk of cardiovascular disease. Credit: Juan Gaertner/Science Photo Library
In early September, pharmaceutical giant Novartis issued a press release that sent shock waves through the cardiology community. A drug called pelacarsen, once expected to be a potential blockbuster, had failed to reduce the risk of heart problems and stroke in people with underlying cardiovascular disease.
More muscle, less belly fat: mutations to a gene are linked to wide-ranging benefits
我没那么确定，现在市场波动太大了。
盘口已经反应得差不多了，进场性价比不高。
新闻里第 3 点才是关键，市场好像还没充分定价。